HUTCHMED Highlights Phase II Data at ESMO

Summary by AI BETAClose X

HUTCHMED announced pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma, showing an objective response rate of 42.5% and a disease control rate of 83.9% in pretreated advanced patients with FGFR2 fusions/rearrangements. The study met its primary endpoint, with a median duration of response of 6.9 months and median progression-free survival of 6.9 months, alongside a median overall survival of 16.6 months. Fanregratinib demonstrated a manageable safety profile with Grade 3 or greater drug-related adverse events in 48.3% of patients, and treatment discontinuation due to adverse events was low at 2.2%. A New Drug Application for fanregratinib has been accepted for priority review by China's NMPA.

Disclaimer*

UK 100

Latest directors dealings